CHMP Nod Little Consolation As Amgen's Imlygic Becomes Melanoma Also-Ran
This article was originally published in The Pink Sheet Daily
Europe's top scientific panel gives positive review to product (also known as T-VEC) for advanced melanoma but the treatment landscape has been transformed by innovative competitors over the past few years.
You may also be interested in...
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.
Merck’s sBLA for Keytruda in lung cancer has been accepted by FDA and granted an Oct. 2 action date, the firm announced. The company also revealed several new research collaborations to study Keytruda in more combination trials at ASCO.
Joint advisory committee votes 22-1 to approve T-VEC for metastatic melanoma but several members favor restricting use to patients in earlier stages of disease; FDA not asking the ‘right question’ for approval, NCI representative says.